Cryo-Cell International, Inc.
Cryo-Cell International, Inc. (CCEL)
Overview
Cryo-Cell International is a Delaware corporation headquartered in Oldsmar, Florida, that describes itself as the world's first private cord blood bank, having pioneered the separation and cryogenic storage of umbilical cord blood stem cells in 1992. The company reported trailing-twelve-month revenue of about $31.1 million (down roughly 2.7% year over year) with a net loss of approximately $2.5 million, and trades on Nasdaq's NYSE American exchange with a market capitalization of roughly $34 million as of September 2026. Cryo-Cell employed 72 full-time and 4 part-time workers as of its fiscal year ended November 30, 2025, operating out of a nearly 18,000-square-foot Florida headquarters plus a 56,000-square-foot processing and storage facility in Durham, North Carolina acquired in 2022. The company says it stores more than 250,000 cord blood and cord tissue specimens worldwide through a network of global affiliates, but its growth story has stalled: revenue is shrinking, and a costly, high-stakes arbitration dispute with Duke University — which terminated a licensing agreement in May 2025 — has put the company's planned expansion into broader cellular therapy on hold.
What They Do & How They Make Money
Cryo-Cell makes money primarily by collecting, processing, and cryogenically storing umbilical cord blood and cord tissue stem cells on behalf of families who pay for the option to use those cells for potential future medical treatment. The core economics are a processing fee plus a first-year storage charge, followed by recurring annual storage/maintenance fees for as long as a family keeps a specimen banked — though many customers instead prepay for 18-year or lifetime storage plans, which smooths but does not eliminate the company's dependence on winning new birth-year customers each year in a shrinking U.S. birth-rate environment. A smaller public cord blood banking business, built around inventory acquired from Cord:Use in 2018, processes and stores donated specimens for use by the broader public through the National Marrow Donor Program, giving the company a second, adjacent revenue stream and a more ethnically diverse specimen pool. A third piece, PrepaCyte-CB, manufactures and sells the processing technology used in cord blood stem cell separation, monetizing Cryo-Cell's own processing know-how rather than the storage relationship itself.
Business Segments
- Private cord blood/tissue banking — The core business: collecting and cryogenically preserving umbilical cord blood and cord tissue stem cells for an individual family's potential future use, generating processing and recurring/prepaid storage fees.
- Public cord blood banking — Processing and storing donated cord blood specimens (built substantially on the 2018 Cord:Use inventory acquisition) for matching against public patients in need of a transplant via the National Marrow Donor Program.
- PrepaCyte-CB manufacturing — Sale of Cryo-Cell's proprietary cord blood stem cell processing technology, a smaller ancillary revenue line tied to the company's core processing expertise.
Competitors
Cryo-Cell's 10-K states that it competes against approximately 25 other national private cord blood banks in the U.S., a fragmented field in which the company emphasizes its AABB and FACT accreditations, cGMP/cGTP regulatory compliance, and claimed 100% specimen-viability track record as points of differentiation. Larger, better-capitalized private banking competitors and international players (some backed by larger healthcare or biotech parents) compete on price, marketing reach to expectant parents via OB-GYNs and hospitals, and increasingly on offering adjacent cellular-therapy services beyond storage alone.
Competitive Position
Cryo-Cell's principal asset is being a long-established, accredited first-mover brand in a niche, trust-sensitive category where parents are choosing a multi-decade storage relationship for their newborn's biological material — a decision few families revisit once made, giving the installed base of stored specimens real switching-cost stickiness. That stickiness, however, has not translated into growth: revenue is declining, the company is unprofitable on a trailing basis, and it is embroiled in litigation with Duke University over a terminated licensing agreement that was central to its strategy of expanding beyond storage into cellular therapy (the proposed Cryo-Cell Institute for Cellular Therapies and Celle Corp. spinoff are both suspended pending arbitration, with a final hearing scheduled for April 2026 and claimed damages exceeding $100 million). The private cord blood banking category itself faces secular headwinds from declining U.S. birth rates and mixed clinical evidence on real-world utilization of banked cord blood, meaning Cryo-Cell's future depends heavily on defending its existing storage annuity, prevailing in or favorably resolving the Duke dispute, and finding a credible path to reignite growth beyond its legacy banking business.